Capital flows back to sensory restoration

Science Corp has closed a $230 million funding round to advance commercialization of its vision restoration technology. The company, founded by Max Hodak after his departure from Neuralink, develops a retinal implant system designed to restore functional sight in patients with severe vision loss.

The funding arrives as the BCI sector fragments into distinct application domains. While motor BCIs capture headlines with paralysis reversal demos, sensory interfaces face different technical constraints. Vision restoration requires high-density electrode arrays that can survive in the chemically hostile environment of the eye while translating digital signals into perceptible images. Science Corp’s approach bypasses damaged photoreceptors entirely, stimulating remaining retinal cells directly.

This represents the largest single raise for a sensory BCI company since Second Sight’s peak funding years, before that company’s 2022 collapse left hundreds of patients with unsupported implants. The contrast matters because it reveals what investors learned from that failure. Second Sight ran out of capital before achieving sustainable reimbursement pathways. Science Corp’s round size suggests backers expect a longer commercialization timeline and are funding accordingly.

Market calculations shift

The target population exceeds 20 million people globally with retinitis pigmentosa, age-related macular degeneration, and similar degenerative conditions. But addressable market depends entirely on reimbursement. Medicare and private insurers remain cautious about coverage for devices that restore partial rather than full function. Science Corp will need to demonstrate not just safety and efficacy, but cost-effectiveness relative to existing low-vision aids.

Hodak’s team has published data showing implant recipients can navigate unfamiliar environments and recognize large letters. That falls short of reading smartphone screens or driving, but exceeds the light-perception-only outcomes of earlier retinal implants. The question becomes whether incremental improvement justifies the estimated $150,000+ procedure cost.

Infrastructure determines outcomes

Success requires more than working hardware. Retinal implants demand surgical expertise, calibration protocols, and long-term patient support. Science Corp must either build this infrastructure or partner with ophthalmology centers willing to invest in specialized training. The company’s capital position now allows both approaches simultaneously, reducing the single-point failure risk that sank competitors.

The BCI industry watches this deployment carefully because sensory restoration offers clearer regulatory pathways than cognitive enhancement. If Science Corp can demonstrate sustainable commercialization, it establishes a template for other sensory modalities waiting behind it.